Brentuximab vedotin: A new age in the treatment of Hodgkin lymphoma and anaplastic large Cell lymphoma;Brentuximab vedotin: Una nueva era en el tratamiento del linfoma Hodgkin y del linfoma anaplásico de células grandes

Annals of Pharmacotherapy

Volumn 46, Issue 3, 2012, Pages 377-383

  Minich, Stephanie S ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Anaplastic large cell lymphoma; Brentuximab vedotin; Hodgkin lymphoma; SGN 35

Indexed keywords

BRENTUXIMAB VEDOTIN; KETOCONAZOLE; PLACEBO; RIFAMPICIN;

ABDOMINAL PAIN; ALOPECIA; ANAPHYLAXIS; ANEMIA; ARTHRALGIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BACKACHE; CHILL; CONSTIPATION; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; INSOMNIA; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LIMB PAIN; LUNG EMBOLISM; MAXIMUM TOLERATED DOSE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROSTATITIS; PRURITUS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RELAPSE; REVIEW; SENSORY NEUROPATHY; SEPSIS; SEPTIC SHOCK; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, LARGE-CELL, ANAPLASTIC;

EID: 84858032909     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q680     Document Type: Review

References (22)

1. Hoppe RT, Mauch PT, Armitage JO, et al. Hodgkin lymphoma. 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins, 2007.
2. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-21.
3. Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005;16:625-33.
4. Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006;12:1065-72.
5. Martinez C, Canals C, Allessandrino E, et al. Relapse of Hodgkin's lymphoma (HL) after autologous stem cell transplantation (ASCT): prognostic factors in 462 patients registered in the database of the EBMT (abstract). J Clin Oncol 2010;28(suppl):7s.
6. Ansell SM. Hodgkin lymphoma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86:852-8.
7. Dearden CE, Johnson R, Pettengell R, et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous Tcell lymphoma). Br J Haematol 2011;153:451-85.
8. Querfeld C, Khan I, Mahon B, Nelson BP, Rosen ST, Evens AM. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options. Oncology 2010;24:574-87
9. Savage KJ, Harris NL, Vose JM, et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111:5496-504.
10. Kewalramani T, Zelenetz AD, Teruya-Feldstein J, et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006;134:202-7.
11. Deutsch YE, Tadmor T, Podack ER, Rosenblatt JD. CD30: an important new target in hematologic malignancies. Leuk Lymphoma 2011;52: 1641-54.
12. Foyil KV, Bartlett NL. Anti-CD30 antibodies for Hodgkin lymphoma. Curr Hematol Malig Rep 2010;5:140-7.
13. Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res 2011;17:6428-36.
14. Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010;16:888-97.
15. Younes A. CD30-targeted antibody therapy. Curr Opin Oncol 2011;23: 587-93.
16. Seattle Genetics. Data on file (014).
17. Package insert. Adcetris (brentuximab vedotin). Bothell, WA: SeattleGenetics, August 2011.
18. Fanale M, Forero-Torres A, Rosenblatt JD, et al. A phase 1 weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012;18: 248-55.
19. Chen R, Gopal AK, Smith SE, et al. Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (abstract). Blood 2010;116:283.
20. Shustov AR, Advani R, Brice P, et al. Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma (abstract). Blood 2010;116:961.
21. Seattle Genetics, Inc. Seattle genetics and millennium report positive data from pivotal trial of brentuximab vedotin (SGN-35) in relapsed or refractory Hodgkin lymphoma at ASH annual meeting. Press release, December 6, 2010. www.seattlegenetics.com (accessed 2011 Oct 27).
22. AmerisourceBergen. www.amerisourcebergen.com/abc (accessed 2012 Feb 22).